MedTrace Logo

Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors

NCT06639256 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 258

Last updated 2026-01-28

No results posted yet for this study

Summary

This is a multi-center, open-label, phase 1/2 study to evaluate the safety, efficacy, and pharmacokinetic (PK)/pharmacodynamic (PD) characteristics of HY07121 in participants with advanced solid tumors.

Conditions

  • Safety
  • Tolerability
  • Efficacy

Interventions

DRUG

Test Product HY07121

HY07121 should be administered intravenously at recommended dose.

Sponsors & Collaborators

  • Sichuan Huiyu Pharmaceutical Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Huiyura666! Yu, Doctor · Shandong Cancer Hospital and Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-24
Primary Completion
2026-05-31
Completion
2026-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06639256 on ClinicalTrials.gov